Clinical trial
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent…
NCT00072930 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00072930 |
|---|---|
| Title | MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer |
| Official title | Phase II, Randomized, Open-Label, Two-Arm, Multicenter Study of MEDI-522, a HuMA Directed Against the Human Alpha V Beta 3 Integrin, in Combination With Docetaxel, Prednisone, and Zoledronic Acid in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | MEDI-522, Docetaxel + Prednisone* + Zoledronic Acid |
| Enrollment | 150 |
| Start date | Dec 1, 2003 |
| Primary completion | Apr 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Nov 17, 2003 |
| Last update posted | Jan 15, 2008 |
| Countries | Belgium, Canada, Hungary, Israel, Poland, Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: